Drag

ONESOURCE SPECIALTY PHARMA LTD

Healthcare ONESOURCE

1218.80INR
41.20 ( 3.50%)

Last update at

Day Range

1160.001229.60
LowHigh

52 Week Range

1209.95 2248.00
LowHigh

Fundamentals

  • Previous Close 1177.60
  • Market Cap 203986.14M
  • Volume240,015
  • P/E Ratio 501.41
  • EBITDA 4896.01M
  • Revenue TTM 15215.49M
  • Revenue Per Share TTM 134.06
  • Gross Profit TTM 10411.77M
  • Diluted EPS TTM 3.55

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Total Revenue
Net Income

Balance Sheet

Total Assets
Total Liabilities

Change in Cash

Breakdown 2025-03-31 2024-03-31 2023-03-31
Type yearly yearly yearly
Income before tax -670.66M -3656.97M -4156.45M
Net income -179.71M -3911.65M -7998.30M
Total Revenue 14448.53M 1719.19M 387.14M
Gross Profit 10098.19M 1014.10M 183.03M
Breakdown 2025-03-31 2024-03-31 2023-03-31
Type yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31
Total assets 75502.42M 13086.11M 20088.08M
Intangible assets 15506.74M 3254.46M 3377.06M
Other current assets 1704.11M - -
Deferred long term liab - - -
Non current assets other - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31
Type yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31
Change in Cash 1430.73M 127.90M -1122.81M
Operating Cash -678.54M -1072.11M -1627.65M
Free Cash Flow -1960.02M -1709.78M -2067.60M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change Price Market Cap (M) P/E Ratio
ONESOURCE
ONESOURCE SPECIALTY PHARMA LTD 		41.20 3.50% 1218.80 203986.14 501.41
BIOCON
Biocon Limited 		-3.90 -1.05% 368.40 569444.73 94.72
ANTHEM
Anthem Biosciences Ltd 		-0.65 -0.11% 606.75 416096.85 91.92
CONCORDBIO
Concord Biotech Limited 		19.10 1.64% 1183.20 140309.66 43.31
BLUEJET
Blue Jet Healthcare Limited 		-8.30 -1.97% 413.00 89232.91 25.36

Profile

OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.

ONESOURCE SPECIALTY PHARMA LTD

Star 1, Opp IIM Bangalore, Bengaluru, India, 560076

Key Executives

Name Title Year Born
Mr. Neeraj Sharma CEO, MD & Director 1972
Mr. Anurag Bhagania Chief Financial Officer 1972
Ms. Allada Trisha Company Secretary & Compliance officer NA
Mr. Arun Kumar Pillai B.Com. Founder & Non-Executive Director 1961
Mr. Biju Mathew Chief Operating Officer NA
Dr. Prateek Gupta Senior VP & Head of Technical Development NA
Mr. Milan Doshi Senior Vice President of Global BD NA
Mr. Ravi Kumar Head of Corporate Strategy & Operational Excellence NA
Mr. Bernhard Thurnbauer Chief Quality Officer NA
Mr. Jeffrey Wong Chief Business Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.